Tumor necrosis factor (TNF) is a polypeptide cytokine that is cytotoxic to some but not all tumor cells. The basis for resistance to the cytotoxic effects of this agent remains unclear. We have studied the development of TNF resistance in human ZR-75-1 breast carcinoma cells. ZR-75-1 cells have undetectable levels of TNF RNA and protein. However, TNF transcripts are transiently induced in these cells by exposure to recombinant human TNF. This induction of TNF RNA is associated with production of TNF-like protein in cell lysates and culture supernatants. Stable resistance to TNF-induced cytotoxicity develops when ZR-75-1 cells are exposed to increased concentrations of TNF. The TNF-resistant cells, designated ZR-75-1R, continuously express TNF transcripts and a TNF-like protein. Furthermore, ZR-75-1R cell supernatants contain cytotoxic activity that is abrogated by polyclonal antibody against TNF. The ZR-75-1R cells also possess TNF receptors that are occupied or down-regulated by the TNF-like protein. These findings thus suggest that (') TNF induces TNF transcripts and production of a TNF-like protein in ZR-75-1 cells and (it) resistance to TNF-induced cytotoxicity is associated with stable TNF expression.
Tumor necrosis factor (TNF) is a polypeptide cytokine that exerts a wide variety of biological effects (1). TNF was originally identified by its ability to cause hemorrhagic necrosis in subcutaneous murine tumors (2) . Subsequent studies showed that TNF is cytotoxic to certain murine and human tumors, both in vitro and in vivo (1-3).
The cytotoxic effects of TNF appear to be cell cycledependent. TNF causes accumulation ofcells in G2 phase and cytolysis in late stages of mitosis (4) . This cytolytic effect is enhanced by inhibitors of RNA and protein synthesis (5, 6) . Tumor cells sensitive and resistant to TNF-induced cytotoxicity have similar numbers of cell surface receptors. Furthermore, both sensitive and resistant cells internalize and degrade TNF after receptor binding (7) . Thus, cell surface receptors appear to be necessary but not sufficient for TNF cytotoxicity (8) (9) (10) . The basis for the sensitivity or resistance of transformed cells to TNF remains unknown.
Exposure of TNF-sensitive L-929 mouse fibroblasts to TNF results in the development of stable TNF resistance (11) . Paradoxically, this TNF-resistant subline produces a TNF-like protein that is cytotoxic to the parent L929 cell line. We recently demonstrated that certain human epithelial tumor cell lines inherently resistant to TNF also produce both TNF mRNA and protein (unpublished work). These findings suggested that production of TNF may be associated with TNF resistance. The present studies investigated this relationship in human breast carcinoma cells sensitive to the cytotoxic effects of TNF in vitro. The results show that TNF treatment induces both TNF expression and resistance to TNF cytotoxicity.
METHODS
Cell Culture. The ZR-75-1 human breast carcinoma cells were obtained from the American Type Culture Collection and grown in RPMI 1640 medium with 10% heat-inactivated fetal bovine serum, 100 units of penicillin per ml, 100 pug of streptomycin per ml, 0.3 mg of L-glutamine per ml, 0.02 mM Hepes, and 1 gg of insulin per ml. The ZR-75-1 cells were sequentially exposed to human recombinant TNF (PAC-4D provided by Asahi Chemical Industry America at 1, 10, and 100 units/ml) (13) . Sensitivity to TNF was assayed in a 96-well culture plate. Ten thousand ZR-75-1 cells were plated into each well and incubated for 5-7 days with increasing concentrations of TNF. The cells were fixed with 2.5% glutaraldehyde, washed, and stained with 0.05% methylene blue for 5 min. The plates were then washed and the dye was released with 0.33 M HCl. The absorbance of each well at 600 nm was determined on an automated plate reader (Bio-Rad). TNF cytolysis was determined as described (11) .
RNA Blot Hybridization Analysis. Total cellular RNA was collected from the ZR-75-1 cells by the guanidinium isothiocyanate/cesium chloride method (14) . The purified RNA (20 ,g ) was analyzed by electrophoresis in 1% agarose/6% formaldehyde gels followed by blot transfer to nitrocellulose paper. The human TNF cDNA (15) was nick-translated to a specific activity of =5 x 108 cpm jig. Hybridization conditions were as described (16) .
Metabolic Labeling of TNF. ZR-75-1 cells were incubated overnight in leucine-free RPMI 1640 medium with [4,5- 3H]leucine (16 (Fig. 1A) . In contrast, the TNF cDNA probe hybridized to a 1.6-kilobase transcript that was detectable in cells treated with TNF for 1 hr. The level of TNF RNA reached a maximum at 3 hr and then subsequently declined to undetectable levels by 12 hr (Fig. 1A) . These transcripts were undetectable following similar exposures to TNF but in the presence of a neutralizing monoclonal antibody (data not shown).
In order to determine whether these TNF transcripts were associated with production of TNF protein, control and TNF-treated ZR-75-1 cells were incubated with [3H]leucine. Cell lysates and culture media were then assayed by immunoprecipitation with rabbit polyclonal antibodies reactive with human TNF. The lysate of TNF-treated cells contained a 17-kDa and a 45-to 50-kDa immunoreactive protein (Fig.  1B) . Furthermore, a labeled 17-kDa TNF-like protein was detected in the culture supernatants of the TNF-treated ZR-75-1 cells but not of the control cells (Fig. 1C) . Thus, treatment of ZR-75-1 cells with TNF appeared to induce production of both TNF RNA and TNF protein.
The ZR-75-1 cells were next exposed to increasing concentrations of TNF. After four passages, a subline was selected that grew in the presence of 10 units of TNF per ml. However, these cells reverted to the TNF-sensitive phenotype after removal of TNF selection. Additional stepwise increases to a TNF concentration of 100 units/ml resulted in the selection of stable TNF-resistant ZR-75-1 cells. This subline, designated ZR-75-1R, was resistant to TNF concentrations of 104 units/ml and has maintained this phenotype for more than 6 months in the absence of TNF.
The ZR-75-1R cells were studied by blot hybridization analysis for the presence of TNF transcripts. The TNF cDNA probe hybridized with both a 1.6-kilobase transcript and a larger RNA species not detected in the TNF-treated ZR-75-1 cells (Fig. 2A) . Moreover, exposure of the ZR-75-1R cells to TNF at 100 units/ml for 3 hr had no detectable effect on either of these transcripts. The expression of TNF at the RNA level was also associated with production of a TNF-like protein. A 17-kDa protein was immunoprecipitated from ZR-75-1R culture supernatant (Fig. 2B) . Moreover, ZR-75-1R supernatant had detectable TNF-like reactivity in the ELISA and contained activity that was cytotoxic to mouse L-929 cells (data not shown). This cytotoxicity was abrogated by treatment with neutralizing antibody against TNF.
The development of ZR-75-1 cell resistance to the cytotoxic effects of TNF may have been related to the loss of cell membrane TNF receptors. We therefore studied the interaction of 125I-TNF with the surface of ZR-75-1 and ZR-75-1R cells. Analysis of the radioiodinated TNF by NaDodSO4/ polyacrylamide gel electrophoresis and autoradiography revealed one band at 17 kDa. Binding of the 125I-TNF to 106 cells was assayed for 1 hr at 37°C. Specific binding was detectable on the sensitive ZR-75-1 cells but not on the resistant ZR-75-1R cells (Fig. 3) results were obtained after a 1-hr treatment with the polyclonal anti-TNF antibody. In contrast, treatment of these cells with an equivalent amount of nonspecific IgG had no effect on TNF binding (Fig. 3) . These results suggest that the ZR-75-1R cells retained detectable TNF receptors. TNF is currently under clinical trial as an antitumor agent. Although these phase I trials are too early to determine efficacy, previous studies suggest that certain human epithelial tumor cells are inherently resistant to the cytotoxic effects of this agent (ref . 3 and unpublished work) . Furthermore, certain human epithelial tumors may be capable of constitutively producing a TNF-like protein that, considering the relationship between TNF and cachectin, may contribute to the cachexia of malignancy (26) . Finally, the present results suggest that treatment of human epithelial tumors with TNF may ultimately lead to the development of TNF resistance and the production of a TNF-like protein. Although the available experimental evidence is derived from in vitro studies, the effective clinical use of TNF may require further insights regarding this development of TNF resistance and approaches to reverse the TNF-resistant phenotype.
